MedWatch

Departing Leo Pharma executive plans to follow Genmab's example for new biotech: "It's a major aspiration, but it's can be done"

Leo Pharma's departing head of R&D wants to create a pharmaceutical venture in his new position as the CEO of Union Therapeutics – inspired by Jan van de Winkel and Genmab.

Future Union Therapeutics CEO Kim Kjøller. | Foto: Leo Pharma / PR

Kim Kjøller's decision to leave the role of Executive Vice President Global Research&Development at Leo Pharma in favor of a CEO position in a minor biotech firm partly owes to his vision of creating a new frontrunner in the Danish pharmaceutical industry.

Kjøller tells MedWatch this in the wake of Tuesday's announcement that he is leaving Leo Pharma to become the CEO of the biotech company Union Therapeutics.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier